ReviewMolecular biology reports2026
Targeting oxidative stress pathways in epilepsy: mechanistic insights into the role of ascorbic acid.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Epilepsy, a neurological disease, is linked to oxidative stress generated due to the synchronous firing of neurons during seizures and use of antiseizure medications (ASMs). Among commonly prescribed ASMs, carbamazepine, valproate, and levetiracetam have been implicated in modulating oxidative stress-related signaling pathways, including Nrf2, NF-κB, and MAPK. Ascorbic acid, a potent antioxidant capable of crossing the blood-brain barrier, has emerged as a promising therapeutic candidate. This review examines the molecular mechanisms underlying ASM-associated oxidative stress in clinical, non-kindled/kindled preclinical, as well as non-epilepsy models, and highlights evidence demonstrating the ability of ascorbic acid to attenuate ROS accumulation, enhance endogenous antioxidant defenses, and modulate redox-sensitive signaling pathways implicated in epileptogenesis and ASM-induced toxicity. Collectively, the available evidence suggests that ascorbic acid has the potential to confer neuroprotection and reduce oxidative injury in epilepsy. Insights presented in this review aim to initiate research focusing on ascorbic acid as an adjuvant in epilepsy. Further studies are warranted to clarify its interactions with ASM metabolism, to optimize dosing strategies, and to establish its translational potential as an adjuvant therapy in clinical epilepsy management.
Indexed as
Identifiers
42240857What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.